Merck plans to invest $1 billion in building a factory in the United States to ensure the supply of Keytruda is not affected by tariffs.

According to the Zhixin Finance APP, Merck (MRK.US) is seeking to invest $1 billion in building a factory in Delaware to expand its manufacturing operations in the United States. With looming tariffs on the industry, Merck has become the latest pharmaceutical company to increase domestic investment in the United States. Media reports on Tuesday stated that the factory will produce a new, user-friendly formula of Keytruda, a blockbuster cancer treatment drug of the company; it will also become the company's first domestic production base for Keytruda in the United States, ensuring that American patients have access to domestically produced drugs.